Roivant科學

2023年1月30日

Roivant還將參加2月份的SVB證券全球生物製藥會議和3月份的Cowen第43屆年度醫療保健會議，瑞士巴塞爾和倫敦，紐約和波士頓，2023年1月30日(GLOBE NEWSWIRE)——Roivant科學(納斯達克:ROIV)今天宣布，將於美國東部時間2023年2月13日(周一)上午8:00舉行現場電話會議和網絡直播，報告截至2022年12月31日的第三季度財務業績，並提供企業更新。要通過電話參加電話會議，請使用此注冊鏈接在線注冊。演示和網絡直播的詳細信息也將在Roivant網站https://investor.roivant.com/news-events/events的投資者部分的“活動和演示”中提供。電話會議結束後，Roivant的網站上可以看到存檔的網絡直播。Roivant還宣布將參加以下即將舉行的投資者會議:SVB證券全球生物製藥會議(2月14日周二)，包括美國東部時間下午12:00舉行的爐邊聊天。Cowen第43屆年度醫療保健會議(3月7日周二)，包括美國東部時間上午11:10舉行的爐邊聊天，以及美國東部時間下午12:50舉行的小組討論。Roivant網站投資者部分的“事件和演示”將提供每場演示的現場網絡直播。Roivant的使命是通過將每一次低效視為機遇，改善為患者提供的醫療保健服務。Roivant通過創新的方式構建技術和培養人才，更快地開發變革性藥物，利用Roivant平台推出Vants -靈活而專注的生物製藥和健康技術公司。欲了解更多信息，請訪問www.roivant.com。Roivant Sciences前瞻性聲明本新聞稿包含前瞻性聲明。 Statements in this press release may include statements that are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), which are usually identified by the use of words such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would” and variations of such words or similar expressions. The words may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. We intend these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Exchange Act. Our forward-looking statements include, but are not limited to, statements regarding our or our management team’s expectations, hopes, beliefs, intentions or strategies regarding the future, and statements that are not historical facts, including statements about the clinical and therapeutic potential of our products and product candidates, the availability and success of topline results from our ongoing clinical trials and any commercial potential of our products and product candidates. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. Although we believe that our plans, intentions, expectations and strategies as reflected in or suggested by those forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a number of risks, uncertainties and assumptions, including, but not limited to, those risks set forth in the Risk Factors section of our filings with the U.S. Securities and Exchange Commission. Moreover, we operate in a very competitive and rapidly changing environment in which new risks emerge from time to time. These forward-looking statements are based upon the current expectations and beliefs of our management as of the date of this press release, and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except as required by applicable law, we assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Contacts